免疫の system `could be trained to 位置／汚点／見つけ出す 麻薬-抵抗力のある 癌s´
The 免疫の system could be trained to identify 麻薬 抵抗力のある 癌s, new 研究 示唆するs.
Scientists say 積極的な 癌s could be 扱う／治療するd with immunotherapies that direct the 免疫の system to kill 癌 独房s with 明確な／細部 麻薬 抵抗-原因（となる）ing 突然変異s.
麻薬 抵抗 突然変異s that 回復する activity of 明確な／細部 遺伝子s as a way of 避けるing the 影響s of 麻薬 治療 could leave tumours 攻撃を受けやすい to the 影響s of immunotherapy, によれば a new 熟考する／考慮する.
熟考する／考慮する leader professor Chris Lord, 副 長，率いる of breast 癌 研究 at the 学校／設ける of 癌 研究 (ICR), London, said: “癌s that have 修理d their BRCA 突然変異s are difficult to 扱う／治療する, as their 独房s have 回復するd some of the 所有物／資産／財産s of normal 独房s ? in many ways this means that there are no obvious vulnerabilities to 的.
“But we often 公式文書，認めるd that the way in which some 癌 独房s 修理 BRCA 遺伝子s (which are important in fighting 癌) means that the proteins that they make are not 完全に normal, and could be recognised by the 免疫の system as foreign, 開始 up ways to 的 and 扱う／治療する these 癌s by using the 免疫の system.
“We could use immunotherapy 麻薬s like 検問所 inhibitors to harness the 団体／死体’s 免疫の 返答, and direct it at 復帰 突然変異s.
免疫の system `could be trained to 位置／汚点／見つけ出す 麻薬-抵抗力のある 癌s´ (Luciana Guerra/PA)
“That has the 可能性のある to open up an exciting new avenue of 治療 for 患者s with 積極的な 癌s that are 抵抗力のある to the best 利用できる 現在の 麻薬s.”
Scientists 熟考する／考慮するd 癌s that had 避けるd the 影響s of platinum chemotherapies and 麻薬s called PARP inhibitors ? which are now licensed for ovarian, breast, pancreatic and prostate 癌s ? by 修理ing their BRCA 遺伝子s.
They 設立する that the new 見解／翻訳／版s of the BRCA1 or BRCA2 遺伝子s were subtly different from the same 遺伝子s in healthy 独房s.
研究員s believe the differences in these 遺伝子s are big enough that it should be possible to train the 団体／死体’s 免疫の system to 位置／汚点／見つけ出す and kill 癌 独房s with the 修理d BRCA 遺伝子s.
PARP inhibitors attack 癌s with BRCA 遺伝子 突然変異s or さまざまな other genetic faults which leave them 攻撃を受けやすい to デオキシリボ核酸 損失.
However, 癌s can sidestep the 影響s of PARP inhibitors or chemotherapy through genetic changes that switch the BRCA 遺伝子s 支援する on ? known as 復帰 突然変異s.
The team from the CRUK 遺伝子 機能（する）／行事 研究室／実験室 and Breast 癌 Now 研究 Centre at the 学校／設ける of 癌 研究 (ICR) 設立する that some BRCA 突然変異s were more likely than others to develop 復帰 突然変異s that 再開するd their 遺伝子 activity.
（悪事，秘密などを）発見するing these 突然変異s could identify 患者s whose 癌s might be 推定する／予想するd to be at higher 危険 of developing 抵抗 to 治療.
Where 復帰 突然変異s occurred, the team 設立する that 修理d BRCA 遺伝子s created proteins which 異なるd from normal 独房s.
Computer models 予報するd that these would often be immunogenic ? meaning that the 免疫の system would recognise them as foreign.
Professor Paul Workman, 長，指導者 (n)役員／(a)執行力のある of the ICR, said: “癌 進化 and 麻薬 抵抗 is the biggest ch allenge we 直面する in 研究 and 治療 today. 熟考する／考慮するs like this are incredibly 価値のある in dissecting out how, why and when 癌s can 発展させる 抵抗 to 現在の 麻薬s.
“Excitingly, this 研究 opens up the 可能性のある for a brand new approach to 治療 that uses 癌’s defences against it, by 的ing the very 突然変異s which give the 病気 抵抗 to 存在するing 麻薬 therapy.”
The 熟考する／考慮する, published in the 癌 発見 定期刊行物, was 基金d by 癌 研究 UK, Breast 癌 Now and the Schottlander 研究 Charitable 信用.
